Correlation of Dasatinib Pharmacokinetics with Clinical Response and Adverse Events in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase

Trial Profile

Correlation of Dasatinib Pharmacokinetics with Clinical Response and Adverse Events in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2015

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 31 Jul 2015 New trial record
    • 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top